Results 191 to 200 of about 310,703 (307)

Correction: Does papillary muscle free strain has predictive value in risk stratification of patients with hypertrophic cardiomyopathy? [PDF]

PLoS One
PLOS One Editors.
europepmc   +1 more source

The HRAS Variant c.175G>A (p.Ala59Thr) Causes a Predominantly Ectodermal Phenotype Lacking Classic Costello Syndrome Features

American Journal of Medical Genetics Part A, Volume 200, Issue 2, Page 407-418, February 2026.
ABSTRACT Costello syndrome (CS) is a rare dominant HRAS RASopathy characterized by curly hair, cardiac abnormalities, craniofacial anomalies, and developmental delay. HRAS codon 58, 59, and 60 variants are associated with milder phenotypes. We describe a three‐generation family with a previously unreported heterozygous HRAS variant c.175G>A (p.Ala59Thr)
Nikole Rautiainen, Eveliina Brandt, Kaisa Kettunen, Outi Elomaa, Sirpa Kivirikko, Leila Jeskanen, Katriina Lappalainen, Nelli Sjöblom, Juha Kere, Katariina Hannula‐Jouppi, Liisa Harjama   +10 more
wiley   +1 more source

Indications for Surgery in Obstructive Hypertrophic Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2021
Mark V. Sherrid
doaj   +1 more source

Isolated Right Ventricular Hypertrophic Cardiomyopathy Mimicking an Intramural Mass in a 13-Year-Old Male. [PDF]

Clin Case Rep
Tingting H, Guotao M, Xiaona L, Ximin S, Yongtai L.   +4 more
europepmc   +1 more source

CYP2C19 genotype testing for clopidogrel: A guideline developed by the UK Centre of Excellence in Regulatory Science and Innovation in Pharmacogenomics (CERSI‐PGx)

British Journal of Clinical Pharmacology, Volume 92, Issue 2, Page 329-347, February 2026.
Clopidogrel, an antiplatelet agent, is currently licensed in the United Kingdom for the prevention and treatment of atherothrombotic events in cerebrovascular disease, coronary artery disease and peripheral arterial disease. Clopidogrel requires metabolic activation by the cytochrome P450 enzyme CYP2C19 to be effective.
Cinzia Dello Russo, Iain Frater, Rebecca Kuruvilla, Stefanie Lip, Hannah O'Neill, Kerry Burke, Vicky Chaplin, Alexander S. F. Doney, Salim Elyas, Nicholas Greaves, Sophie Harding, David Hargroves, Judith Hayward, Dyfrig A. Hughes, Tom A. T. Hughes, Sree Kondapally, Patrick Mok, Aaron Peace, Imran Rafi, Simon Ray, Vicky Stinton, Luigi Venetucci, Munir Pirmohamed   +22 more
wiley   +1 more source

Social survey on knowledge, attitude and practice of hypertrophic cardiomyopathy. [PDF]

Front Cardiovasc Med
Lan W, He B, Hu S.
europepmc   +1 more source

Rationale and Design of the Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure

Clinical Cardiology, Volume 49, Issue 2, February 2026.
The COPILOT‐HF trial is a pragmatic, randomized study designed to determine if a remote, pharmacist‐led navigator‐driven intervention with patient and provider education is more effective than patient and provider education alone at improving the implementation of guideline‐directed medical therapy for patients across the full spectrum of heart failure.
Alexander J. Blood, Ozan Unlu, John W. Ostrominski, Shahzad Hassan, Hunter Nichols, Samantha Subramaniam, Daniel Gabovitch, Jacqueline Chasse, Marian McPartlin, Christian Figueroa, Emma Collins, Megan Twining, Matthew Varugheese, Kavishwar Wagholikar, Christopher P. Cannon, Akshay S. Desai, Benjamin M. Scirica   +16 more
wiley   +1 more source

Beyond Hypertrophy: A Case of Mid-ventricular Obstructive Hypertrophic Cardiomyopathy With Apical Sequestration. [PDF]

Cureus
Taoussi O, Scadi S, Mokhtari M, Benouna G, Merzouk F.   +4 more
europepmc   +1 more source

INFECTIVE ENDOCARDITIS DUE TO GEMELLA-MORBILLORUM COMPLICATING HYPERTROPHIC OBSTRUCTIVE CARDIOMYOPATHY [PDF]

, 1994
Campbell, NP, Kerr, JR, McGimpsey, JG, Webb, CH   +3 more
core   +1 more source

[Hypertrophic cardiomyopathy. Arrhythmia in hypertrophic cardiomyopathy].

Archivos de cardiologia de Mexico, 2003
Hypertrophic cardiomyopathy is a relatively common genetic disorder with heterogeneity in mutations, forms of presentation, prognosis and treatment strategies. Hypertrophic cardiomyopathy is recognized as the most common cause of sudden cardiac death that occurs in young people, including athletes.
openaire   +1 more source